Major Depressive Episode

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Mission Therapeutics
Mission TherapeuticsUK - Cambridge
2 programs
1
1
KetaminePhase 41 trial
KetaminePhase 21 trial
Active Trials
NCT01441505Unknown42Est. Dec 2014
NCT00680433Completed83Est. Oct 2012
Takeda
TakedaTOKYO, Japan
1 program
Pen and Paper Digit Symbol Substitution TestN/A1 trial
Active Trials
NCT03999567Completed30Est. Feb 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mission TherapeuticsKetamine
Mission TherapeuticsKetamine
TakedaPen and Paper Digit Symbol Substitution Test

Clinical Trials (3)

Total enrollment: 155 patients across 3 trials

Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)

Start: Apr 2008Est. completion: Oct 201283 patients
Phase 4Completed

A Study of Ketamine as an Antidepressant

Start: Sep 2011Est. completion: Dec 201442 patients
Phase 2Unknown
NCT03999567TakedaPen and Paper Digit Symbol Substitution Test

Validation Study: Mobile DSST on Cognition in Adults With MDD

Start: Aug 2019Est. completion: Feb 202030 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space